Clinical trials: Metastatic Cutaneous Squamous Cell Carcinoma
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck
Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
This clinical trial tests the impact of offering hearing tests (audiometry) close to home and remotely on participation in monitoring for treatment-related hearing loss in patients with head and neck squamous cell cancer…
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06662058
- Testing
- Audiometric Test, Interview
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Emory University
Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma
Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma
This phase II trial studies how well erlotinib works in treating participants with skin squamous cell carcinoma that has spread to other places in the body or has come back.
- Trial name
- NCT01198028
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma
TIL Therapy in cSCC and MCC
The purpose of this research study is to test the safety and effectiveness of a tumor-infiltrating lymphocyte (TIL) cellular therapy, also called LN-145 or lifileucel, and chemotherapy in combination with Interleukin-2 (IL-2) to…
- Conditions
- Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma, Skin Cancer
- Trial name
- NCT07288073
- Testing
- LN-145, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Karam Khaddour, MD, MS
Cutaneous Squamous Cell Carcinoma
Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
The objective of this program is to provide access to cemiplimab (REGN2810) to patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced cutaneous squamous cell carcinoma (laCSCC) who are not…
- Trial name
- NCT03492489
- Testing
- cemiplimab
- Sponsor
- Regeneron Pharmaceuticals
Cutaneous Squamous Cell Carcinoma (CSCC), Advanced Cutaneous Squamous Cell Carcinoma
D-TECT: Pretreatment D-dimers and Disease Control in Advanced cSCC Treated With Cemiplimab
D-TECT is a prospective, multicenter, non-interventional observational study investigating whether pretreatment D-dimer levels predict disease control in patients with locally advanced or metastatic cutaneous squamous cell…
- Conditions
- Cutaneous Squamous Cell Carcinoma (CSCC), Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
- Trial name
- D-TECT (NCT07684066)
- Testing
- Pretreatment D-dimer status
- Where
- 15 sites in Austria, Germany
- Volunteers
- 116 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Carcinoma, Squamous Cell, Skin Cancer
Time to Treatment and Disease-free Survival of Patients With High-risk Head-neck Cutaneous Squamous Cell Carcinoma
The purpose of this study is to investigate the association between time to treatment (defined as date of pathological diagnosis to date of start treatment) and disease free survival in patients with high risk cutaneous squamous…
- Conditions
- Carcinoma, Squamous Cell, Skin Cancer, Carcinoma, Squamous Cell, Skin, Carcinoma, Squamous Cell of Head and Neck
- Trial name
- NCT05845632
- Testing
- Treatment
- Where
- 2 sites in Netherlands
- Volunteers
- 965 people
- Sponsor
- Maastricht University Medical Center
PDL1 Gene Mutation, Non Small Cell Lung Cancer
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
This is a Phase 0/1, First-in-Human (FIH), study to evaluate safety, tolerability of 177Lu-RAD204 in participants with selected solid tumors, and to determine the MTD and/or recommended dose for future exploration.
- Conditions
- PDL1 Gene Mutation, Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), TNBC, Triple Negative Breast Cancer
- Trial name
- NCT06305962
- Testing
- 177Lu-RAD204
- Where
- 6 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Radiopharm Theranostics, Ltd
Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC)
A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors
This clinical trial is evaluating a drug called MDSY-2140 in participants with hematologic malignancies and advanced solid tumors.
- Conditions
- Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer Metastatic
- Trial name
- NCT07899632
- Testing
- MDSY-1240
- Volunteers
- 75 people
- Sponsor
- Medsyn Biopharma, LLC
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Open-label study using ASP-1929 photoimmunotherapy in combination with anti-PD1 therapy in patients with recurrent or metastatic head and neck and squamous cell cancer or advanced or metastatic cutaneous squamous cell carcinoma.
- Conditions
- Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
- Trial name
- NCT04305795
- Testing
- 200 mg Pembrolizumab, 350 mg Cemiplimab, ASP-1929 PIT
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Rakuten Medical, Inc.
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Cutaneous Squamous Cell Carcinoma
The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)
Following basal cell carcinoma, Cutaneous Squamous Cell Carcinoma (CSCC) is the most common skin cancer and its incidence remains on a steady rise.
- Trial name
- NCT05238363
- Testing
- HLX07
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Henlius Biotech
Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life.
- Conditions
- Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8
- Trial name
- NCT06265285
- Testing
- Home Health Encounter, Nivolumab, Patient Monitoring
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Squamous Cell Carcinoma of the Skin
Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin
This study intends to conduct a single-arm, prospective and open clinical study, using carrellizumab combined with albumin-binding paclitaxel regimen for first-line treatment of squamous cell carcinoma of the skin, including 24…
- Trial name
- NCT05886140
- Testing
- Carrilizumab with albumin-binding paclitaxel
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Henan Cancer Hospital
Cutaneous Squamous Cell Carcinoma
Treatment With Nab-paclitaxel in Cutaneous SCC
This is an investigator initiated phase II study to assess the efficacy of a chemotherapy called nab-paclitaxel as first line cytotoxic chemotherapy in subjects with unresectable locally advanced or metastatic cutaneous squamous…
- Trial name
- NCT02076243
- Testing
- nab-paclitaxel
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Malignant Melanoma, Squamous Cell Carcinoma of Skin
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
Primary Objective: -To determine the antitumor activity of SAR444245 in combination with cemiplimab. Secondary Objectives: To determine the recommended phase 2 dose and to assess the safety profile of SAR444245 when combined with…
- Trial name
- NCT04913220
- Testing
- THOR-707, Cemiplimab
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 46 people
- Sponsor
- Sanofi
Advance Directives, Oncology
ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS
The law about advance directives is evolving but, in France, few people write it. Te main endpoint of this research is to estimate the proportion of patients who have written their advance directives or considering doing so in…
- Conditions
- Advance Directives, Oncology, Skin Cancer, Melanoma
- Trial name
- PADAONCODERM (NCT03822988)
- Testing
- no intervention, only complete a survey
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Central Hospital, Nancy, France
Squamous Cell Carcinoma
Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)
The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in adult participants with recurrent or metastatic(R/M) cutaneous Squamous Cell Carcinoma (cSCC) or locally advanced (LA) unresectable…
- Trial name
- NCT03284424
- Testing
- Pembrolizumab
- Where
- 59 sites in United States, Australia and 8 more
- Volunteers
- 159 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma, Skin Cancer
The Aim of This Study is to Demonstrat That Vacuum-assisted Closure Versus Conventional Wound Closure Enables to Diminish Local Complications After Lymph Node Dissection in Patients With Metastatic Skin Tumors
In this study, we compared a negative pressure wound therapy, versus a conventional dressing in order to evaluate the most efficient wound therapy closure after axillary and inguinal lymph nodes dissections in the management of…
- Conditions
- Melanoma, Skin Cancer, Epidermoid Carcinoma, Neuroendocrine Carcinoma
- Trial name
- NCT04583605
- Testing
- PREVENA
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Central Hospital, Nancy, France
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Non-melanomatous Skin Cancer
Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PEG-interferon alfa-2a may interfere with the growth of tumor cells and slow the growth of skin cancer.
- Trial name
- NCT00423397
- Testing
- PEG-interferon alfa-2a, gefitinib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Diego